Armodafinil

Armodafinil is the R-(minus)-enantiomer of modafinil, a wakefulness-promoting compound (a eugeroic) marketed under the brand name Nuvigil. Modafinil is a racemic mixture of R- and S-enantiomers, and because the R-enantiomer has a substantially longer half-life than the S-form, armodafinil was developed to provide a purified, longer-lasting single-isomer version that maintains higher plasma concentrations later in the day ^[1]. It is a benzhydryl sulfinyl compound and is chemically and functionally distinct from amphetamine-type stimulants.

Armodafinil is approved by the US Food and Drug Administration to improve wakefulness in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (as an adjunct to airway treatment), and shift work disorder. Its clinical evidence base is substantial; randomized, double-blind trials in sleep apnea patients adherent to nasal continuous positive airway pressure showed that armodafinil significantly increased objective sleep latency on the Maintenance of Wakefulness Test, improved episodic memory and daily functioning, and reduced fatigue ^[1][2]. Beyond its approved uses it has been studied off-label for cognitive and fatigue-related indications, including radiation-induced fatigue in brain tumor patients, cancer-related fatigue, and as an augmentation agent for the negative symptoms of schizophrenia, with mixed or modest results ^[3][4][6].

As a scheduled prescription medication, a controlled substance in many jurisdictions, armodafinil is used clinically and also widely off-label as a cognitive enhancer and smart drug. It is supplied as oral tablets and is generally well tolerated, with headache the most commonly reported adverse effect ^[1].

Common adverse effects (NUVIGIL label, pooled controlled trials, armodafinil versus placebo): headache 17% versus 9%, nausea 7% versus 3%, dizziness 5% versus 2%, insomnia 5% versus 1%. Headache, rash, depression, dry mouth, insomnia and nausea are dose-related and more frequent at 250 mg than 150 mg. Over 12 months or more (n=743): headache 25%, nasopharyngitis 17%, insomnia 14%; 13% discontinued for adverse events; blood pressure rose a mean 3.6/2.3 mmHg and heart rate 6.7 bpm, most of it within the first 3 months (PMID 20957846).

Serious warnings (label sections 5.1 to 5.7, no boxed warning): serious dermatologic reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis; DRESS and multiorgan hypersensitivity, median onset about 13 days; angioedema and anaphylaxis; persistent sleepiness despite treatment; psychiatric symptoms, with caution advised in anyone with a history of psychosis, mania or depression; impaired ability to drive or operate machinery; cardiovascular events, with the drug to be avoided in mitral valve prolapse patients who have had a prior CNS stimulant syndrome. Any rash is a stop signal until proven unrelated.

Hepatic: in the positive bipolar depression trial, the 200 mg arm produced two serious events, one fatal hepatic failure and one acute hepatitis; investigators did not attribute the death to study drug (PMID 25099397). FDA DILIrank, as mirrored in ChEMBL, classifies armodafinil as ambiguous DILI concern, severity class 3.

Abuse and dependence: DEA Schedule IV in the United States. The label states that abuse has been reported, with euphoric mood and escalating or recurrent use, and that physical dependence can occur, with withdrawal on abrupt cessation including shaking, sweating, chills, nausea, vomiting, confusion, aggression and atrial fibrillation. Preclinically both modafinil enantiomers fully substituted for cocaine in mice trained to discriminate cocaine, but at roughly 8 to 11 times lower potency and with a shallow, slow, low-ceiling dopamine rise rather than cocaine's sharp spike, which is the mechanistic argument for low but non-zero abuse liability (PMID 22537794).

Interactions: moderate CYP3A4/5 induction means hormonal contraceptives can fail; the label directs an additional barrier method or a non-hormonal method during treatment and for one month after stopping. Cyclosporine, midazolam and triazolam exposure falls. Moderate CYP2C19 inhibition raises exposure to omeprazole, phenytoin and diazepam. Carbamazepine and armodafinil each lower the other (carbamazepine AUC down 25%, armodafinil AUC down 37%; PMID 25438721). Monitor prothrombin time and INR with warfarin. Caution with MAO inhibitors.

Pregnancy and lactation: the US label does not contraindicate use, but reports that intrauterine growth restriction and spontaneous abortion have occurred with armodafinil and modafinil, and directs enrolment in the pregnancy exposure registry. The registry's final 14-year analysis found major congenital malformations in 13.1% of prospective live births (18/137, 95% CI 8.0 to 20.0) versus a 3% population rate (PMID 41070135). Regulators in the EU, UK and Australia have since 2019 contraindicated modafinil and armodafinil in pregnancy and in women of childbearing potential not using effective non-hormonal contraception; the FDA has not matched that action. No human milk data appear in the label; a LactMed monograph exists (PMID 30000986).

Anti-doping: modafinil is on the WADA Prohibited List under S6.A, non-specified stimulants, prohibited in-competition only. Armodafinil is R-modafinil and is not separately enumerated; it is covered as modafinil, so a competing athlete needs a Therapeutic Use Exemption. For 2026 WADA newly added flmodafinil and fladrafinil to S6.A as analogues; those are different compounds and are not armodafinil.

Regulatory status: first approved in the US in June 2007 (NUVIGIL, Cephalon, now Teva); prescription-only, generics available; ATC N06BA13. Not approved for ADHD, depression, bipolar disorder, schizophrenia, cancer fatigue or cognitive enhancement in any major jurisdiction.

Armodafinil induces CYP3A4/5 and can reduce the plasma levels and efficacy of CYP3A substrates, most notably steroidal contraceptives; the label advises alternative or additional non-hormonal contraception during use and for one month after discontinuation, and reduced exposure is also expected for cyclosporine and midazolam. It inhibits CYP2C19, which can raise concentrations of substrates such as phenytoin, diazepam, propranolol, and omeprazole and may require dose reduction of those drugs. Armodafinil also suppresses CYP2C9 modestly, so warfarin monitoring is recommended, and induces CYP1A2. These interactions mirror those of racemic modafinil and are documented in the Nuvigil prescribing information. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Armodafinil is the longer-lived R-enantiomer of modafinil, isolated and developed by Cephalon as a follow-on wakefulness-promoting agent. Modafinil itself is a racemic mixture of two mirror-image forms, and researchers found that the R-enantiomer persists longer in the blood, sustaining alertness later into the day. The United States Food and Drug Administration approved armodafinil, sold as Nuvigil, in June 2007 for excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder. Since then it has also been investigated off-label and in trials for conditions such as cancer-related fatigue, depression, and jet lag.

Armodafinil enjoys a strong reputation as a wakefulness aid that delivers durable daytime alertness with far less of the jittery overstimulation, cardiovascular load, and crash associated with classical stimulants. In controlled trials it reliably improves objective measures of wakefulness along with fatigue and certain memory tasks, which has made it a favored tool both for approved sleep disorders and, more informally, for sustained focus. Users often prefer its single-enantiomer design for smoother, longer-lasting coverage across a working day. It is not without trade-offs, including insomnia if taken too late, headache, and dry mouth, and it carries the caution appropriate to any stimulant-adjacent medication.